Note 27 – Basic earnings per share and diluted earnings per share2012 2011Consolidated net income attributable to <strong>the</strong> Group (in euros) 20,399,000 14,427,000Weighted average number of shares outstanding in <strong>the</strong> period 3,050,046 3,050,046Net earnings per share 6.69 4.732012 2011Consolidated net income attributable to <strong>the</strong> Group (in euros) 20,399,000 14,427,000Annual savings of interest net of tax at <strong>the</strong> market rate and resulting from <strong>the</strong>exercise of stock options101,863 170,703Consolidated net income after dilution (in euros) 20,500,863 14,597,703Total number of potential shares 3,185,346 3,260,983Net diluted earnings per share 6.44 4.48Note 28 – Post-closing eventsNoneNote 29 – 2012 Appropriation of incomeOn 5 March 2013, <strong>the</strong> Board of Directors ruled on <strong>the</strong> consolidated financial statements for <strong>the</strong> period ending31 December 2012. These financial statements will become definitive only after <strong>the</strong>y have been approved by<strong>the</strong> Annual General Meeting of <strong>the</strong> shareholders. The Board of Directors will propose <strong>the</strong> distribution of a netdividend of €2 per share, compared with €1.80 for 2011. The total amount of dividends to be distributed willconsequently be €6,100,000.Note 30 – Auditors' feesIn thousands of eurosDeloitte & AssociésHorwath Audit FranceAmount % Amount %2012 2011 2012 2011 2012 2011 2012 2011AuditWork as statutory auditors,certification, auditing ofcorporate and consolidatedfinancial statements:- Issuer 95 83 35% 32% 95 83 42% 36%- Fully consolidated subsidiaries 173 156 64% 55% 111 109 49% 47%O<strong>the</strong>r procedures and servicesdirectly related to <strong>the</strong> mission of<strong>the</strong> statutory auditors:- Issuer 30 11% 19 36 9% 15%- Fully consolidated subsidiaries 2 10 1% 2% 4 2%Subtotal 270 279 100% 100% 225 232 100% 100%O<strong>the</strong>r procedures and services 13 9Total 283 288 225 232109
Note 31 – Consolidated companiesOwnershipCountry of<strong>Registration</strong> numberinterest /Companyregistration or(Siren)Controllingincorporationinterest308,491,521 <strong>Guerbet</strong> SA France 100%308,412,434 Simafex France 100%340,598,978 Medex France 100% 1<strong>Guerbet</strong> GmbH Germany 100%<strong>Guerbet</strong> Ges.m.b.H Austria 100%SA <strong>Guerbet</strong> nv Belgium 100%Laboratorios Farmaceuticos <strong>Guerbet</strong> SA Spain 100%<strong>Guerbet</strong> Laboratories Ltd United Kingdom 100%<strong>Guerbet</strong> Nederland BV Ne<strong>the</strong>rlands 100%<strong>Guerbet</strong> SpA Italy 100%Martins & Fernandes Portugal 100%<strong>Guerbet</strong> AG Switzerland 100%<strong>Guerbet</strong> AS Turkey 100%<strong>Guerbet</strong> Produtos Radiologicos Brazil 100%<strong>Guerbet</strong> Mexicana Mexico 100%<strong>Guerbet</strong> LLC USA 100%<strong>Guerbet</strong> Korea South Korea 100%<strong>Guerbet</strong> Asia Pacific Ltd Hong Kong 100%<strong>Guerbet</strong> Japan Japan 100%<strong>Guerbet</strong> Taiwan Co Ltd Taiwan 100%1 Of which 40% to be acquired under <strong>the</strong> terms of a reciprocal agreement between <strong>Guerbet</strong> and a non-controlling shareholder.110